USPHHealthcare · Medical Care FacilitiesThe 7 Wall Street analysts covering U.S. Physical Therapy, Inc. hold a median 12-month price target of $98 — +9.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores U.S. Physical Therapy, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (74): The share price has been relatively steady.
Quality (44): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on USPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Sept 2026 | JP Morgan | Maintains | Overweight | $90 → $95 |
| 10 Aug 2026 | Barrington Research | Maintains | Outperform | — |
| 10 Aug 2026 | Barrington Research | Maintains | Outperform | $90 → $98 |
| 24 June 2026 | Citizens | Reiterates | Market Outperform | — |
| 24 June 2026 | Citizens | Reiterates | Market Outperform | $98 |
| 13 May 2026 | Barrington Research | Maintains | Outperform | — |
| 8 May 2026 | Citizens | Maintains | Market Outperform | — |
| 10 Mar 2026 | Jefferies | Assumes | Buy | $102 |
| 20 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 5 Jan 2026 | Barrington Research | Maintains | Outperform | — |
| 24 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 24 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 18 Sept 2025 | JP Morgan | Assumes | Overweight | $110 |
| 8 Aug 2025 | Barrington Research | Maintains | Outperform | — |
| 1 July 2025 | Barrington Research | Maintains | Outperform | — |
| 22 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 19 Mar 2025 | JP Morgan | Maintains | Overweight | — |
| 28 Feb 2025 | Barrington Research | Maintains | Outperform | — |
| 16 Dec 2024 | B of A Securities | Upgrade | Buy | — |
| 16 Dec 2024 | JMP Securities | Initiates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
USPH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, U.S. Physical Therapy, Inc. returned +5.1% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 57% of US stocks
Cheaper than 32% of US stocks
Cheaper than 15% of US stocks
Higher than 49% of US stocks
Higher than 21% of US stocks
Higher than 20% of US stocks
Higher than 66% of US stocks
Higher than 57% of US stocks
Higher than 56% of US stocks
Higher than 72% of US stocks
Higher than 80% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
U.S. Physical Therapy, Inc. has a market value of $1.3B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $812.2M. The latest quarter grew 8.5% year on year.
Net income over the same four quarters: $49.9M, a 6.1% net margin.
Diluted earnings per share, trailing twelve months: $0.17.
Free cash flow in the twelve months to 30 June 2026: $64.1M.
Trailing P/E: 474.6×; forward P/E: 25.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.16%, paying out 1011% of earnings.
U.S. Physical Therapy, Inc. employs 4,653 people — $175K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own U.S. Physical Therapy, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks says U.S. Physical Therapy’s Q3 2026 headline results offer one view of its performance for the quarter ended September 2026. The item suggests also comparing key metrics with Wall Street estimates and year-ago values.
Why it matters — Those comparisons may give USPH watchers additional context on quarterly performance beyond the top- and bottom-line numbers.
U.S. Physical Therapy reported third-quarter earnings of $0.80 per share, above the Zacks Consensus Estimate of $0.76. Earnings were $0.66 per share in the year-ago quarter.
Why it matters — The earnings beat and year-over-year increase are relevant to USPH watchers assessing the company’s quarterly results.
U.S. Physical Therapy reported third-quarter 2026 net revenue of $223 million, up 13% from the third quarter of 2025. The headline also cites record-high visits and revenue per visit.
Why it matters — The results highlight growth in revenue alongside record levels of clinic visits and revenue per visit, metrics relevant to tracking USPH's operating performance.
In its Q3 2026 portfolio activity, Aristotle said U.S. Physical Therapy may benefit from an aging population, rising demand for outpatient rehabilitation, and continued industry consolidation.
Why it matters — The commentary highlights demographic and industry trends that the portfolio manager sees as potentially relevant to USPH.
U.S. Physical Therapy said it will report results for the three and nine months ended September 30, 2026, after market close on November 4, 2026. The company scheduled a conference call for the following morning, November 5.
Why it matters — The dates indicate when USPH watchers can expect the company's quarterly financial results and related conference call.
The 7 Wall Street analysts covering U.S. Physical Therapy, Inc. have a median 12-month price target of $98, with estimates ranging from $95 to $101. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering U.S. Physical Therapy, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks U.S. Physical Therapy, Inc. 61 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, U.S. Physical Therapy, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (74 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +9.9% from the last close, and Ticker Nerd's factor model ranks U.S. Physical Therapy, Inc. 61 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering U.S. Physical Therapy, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for USPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $95 to $101 over the next 12 months.
U.S. Physical Therapy, Inc. returned +5.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
U.S. Physical Therapy, Inc.
The most recent item we track (Zacks Investment Research, 5 Nov 2026): "Here's What Key Metrics Tell Us About U.S. Physical Therapy (USPH) Q3 Earnings". Zacks says U.S. Physical Therapy’s Q3 2026 headline results offer one view of its performance for the quarter ended September 2026. The item suggests also comparing key metrics with Wall Street estimates and year-ago values.
U.S. Physical Therapy, Inc. is a healthcare services company that operates outpatient physical therapy clinics across the United States. The company provides pre- and post-operative rehabilitation, treatment for orthopedic, sports-related, neurologic, and work-related injuries, as well as preventive care for patients recovering from surgery or injury. Its business also includes industrial injury prevention services, which support employers with onsite injury prevention, ergonomic assessments, functional evaluations, and rehabilitation-focused workplace solutions. U.S. Physical Therapy, Inc. also manages physical therapy facilities for third parties, including hospitals and physician groups. Through its clinic network and employer-focused services, the company plays a specialized role in rehabilitation care and occupational health delivery within the broader medical services market.
CEO Mr. Christopher J. Reading · 4,653 employees · United States · https://www.usph.com
